Allergan on Thursday touted data from two late-stage trials that showed a drug it in-licensed from a Swiss biotech proved non-inferior to Lucentis in the …

Allergan plans to sell its women’s health and infectious disease units, aiming to shore up investor confidence and more narrowly focus the company amid a …

Brief: Allergan CEO Brent Saunders said Monday the Irish pharma is considering a wide range of business options, including further divestitures or a split of …